Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$40.37 USD
-0.68 (-1.66%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $40.39 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
APLS 40.37 -0.68(-1.66%)
Will APLS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APLS
Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
Other News for APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
Stifel Nicolaus Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)
Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Apellis initiated with neutral view at Piper Sandler, here's why
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts